Alberto L Epstein, et al.

The FDA has recently approved Krystal biotech's beremagene gep erpavec (B-ⅤEC, Ⅴyjuvek) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients. This represents a giant step, not only toward the treatment of this devastating disease, but also for the whole field of non-replicative (nr) recombinant HSⅤ-1 vectors for gene therapy. To view this Bench to Bedside, open or download the PDF.